Additional Advances in MCED Technologies With Charles Vega, MD
Expert Perspectives · Keira Smith · 2025-07-21
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights into the potential of these cutting-edge tests and advice for counseling patients about how to choose the most appropriate cancer screening method for them.
This interview is also available as a 3-part podcast. Listen here to Module 1, Module 2, and Module 3!
Click the links below for the full CME activity!
And view the slide decks here for Module 1, Module 2, and Module 3.
The Science Behind MCED Testing
MCED testing is an emerging technology that enables the detection of multiple cancers through a single blood test. Unlike traditional screening methods that focus on a limited number of cancers—such as breast, colorectal, and cervical—MCED tests have the potential to identify over 50 types of cancer, many of which currently lack routine screening protocols. Dr. Vega highlights the impact of these tests, explaining, “MCED has the promise of detecting many different types of cancer earlier and overall making a significant reduction in cancer mortality in the US and beyond.”
By identifying cancers at an earlier stage, MCED testing may improve patient outcomes and decrease mortality rates. However, as Dr. Vega emphasizes, these tests are still screening tools rather than definitive diagnostic measures. Patients with positive results require follow-up testing to confirm the presence of cancer, just as mammograms and stool-based tests require further examination for a conclusive diagnosis.
Clinical Evidence for MCED Testing
Research is rapidly expanding to evaluate the effectiveness of MCED testing. Large-scale trials, including studies conducted by the National Health Service in the United Kingdom and the US Veterans Affairs health system, are assessing the accuracy and clinical utility of these tests. The goal is to determine how well MCED screening influences cancer detection rates and overall patient survival.
Dr. Vega is particularly interested in how these tests could benefit cancer survivors who are at risk for recurrence or secondary cancers. He states, “If you have a history of childhood cancer, you’re at increased risk of other forms of cancer as you grow into adulthood. These patient populations could really benefit from MCED testing.”
Additionally, studies examining the repeatability of MCED testing indicate that even patients with initially negative results may benefit from periodic screening. The data suggest that a small yet significant percentage of cancers emerge upon retesting within a year, reinforcing the value of continuous monitoring.
Implementing MCED Testing in Clinical Practice
While MCED technology presents significant promise, its integration into routine practice requires careful consideration. Shared decision making plays a crucial role in determining which patients are most appropriate for testing. According to Dr. Vega, high-risk individuals—such as those with a strong family history of cancer, smoking history, or previous cancer diagnoses—may benefit the most from MCED screening.
“The more risk factors a patient has, the more likely MCED screening will be beneficial,” Dr. Vega explains. He also acknowledges the importance of patient counseling, noting that healthcare professionals must guide patients through the process, explaining the limitations and necessary follow-ups associated with positive test results.
Continuing Education for the Multidisciplinary Team
With MCED testing representing a paradigm shift in cancer screening, staying informed is critical for clinicians. Dr. Vega’s three-part microlearning activity offers an in-depth exploration of the science, clinical evidence, and practical application of MCED technology. The activity provides a balanced perspective, helping healthcare providers navigate the complexities of integrating MCED into patient care. As MCED testing continues to evolve, informed clinicians will be better equipped to guide patients through this promising advancement in cancer detection.
About Dr. Vega
Charles Vega, MD, is a Clinical Professor in Department of Family Medicine at the University of California (UC) Irvine. He is also Director of the UC Irvine Program in Medical Education for the Latino Community and Assistant Dean for Culture and Community Education at the UC Irvine School of Medicine. Dr. Vega specializes in Family Medicine, and his academic interests focus on access to quality medical care for underserved populations and the development of training programs to promote compassionate healthcare. He has given over 200 invited presentations at national and regional conferences, and he has authored more than 1,000 continuing medical education reviews.